LETTER

Catheter retention as a consequence rather than a cause of unfavorable outcome in candidemia

Lauro Damonti¹, Véronique Erard^{1,2}, Jorge Garbino³, Jacques Schrenzel⁴, Stefan Zimmerli⁵, Konrad Mühlethaler⁵, Alexander Imhof^{6,8}, Reinhard Zbinden⁷, Jan Fehr⁸, Katia Boggian⁹, Thomas Bruderer¹⁰, Ursula Flückiger^{11,14}, Reno Frei¹², Christina Orasch^{1,13,14}, Anna Conen^{14,15}, Nina Khanna¹⁴, Thomas Bregenzer^{15,16}, Jacques Bille¹⁷, Frédéric Lamoth^{1,17}, Oscar Marchetti^{1,18*}, Pierre-Yves Bochud^{1*} and Fungal Infection Network of Switzerland (FUNGINOS)

© 2017 Springer-Verlag Berlin Heidelberg and ESICM

Dear Editor,

Candidemia is an important cause of mortality and morbidity in the hospital setting [1]. Central venous catheters (CVC) can be the primary source of fungemia, as a result from external infection of the line. Alternatively, secondary CVC infection can occur during bloodstream dissemination of Candida from the patient's intestinal flora, especially during prolonged neutropenia or following abdominal surgery. Removing the CVC seems, in principle, a logical step, as Candida biofilms are difficult to eradicate from a foreign body by the sole use of antifungal drugs [1]. However, the literature supporting CVC removal is controversial [2-4]. We hypothesized that inconsistent reports among studies may result from the inability to measure factors that are inherent to the daily clinical practice, but difficult to record, such as the time at which blood culture results are obtained (sometimes post-mortem) and the clinical context which can rapidly evolve from maximal care to care withdrawal.

To test this hypothesis, we analyzed the role of catheter removal in the outcome of 444 adult candidemic patients with a CVC in place from 27 Swiss hospitals (supplemental

Clinical and Microbiology Laboratory Investigators of the FUNGINOS network are listed in the Appendix 1 in Electronic Supplementary Material.

Table 1), including 158 ICU and 286 non-ICU patients. Risk factors associated with crude mortality were assessed by univariate analyses (supplemental Table 2) and multivariate logistic regression models (Table 1) by using variables that were significantly associated with the endpoint in univariate analyses (cutoff P value = 0.15). We built a first model that did not include care withdrawal decision and post-mortem diagnosis of candidemia as variables (model 1) and compared it to a second model that did (model 2). We also developed a model that excluded patients fulfilling these two criteria (model 3). Modified logistic regression models according to a method by Firth [5] were used to overcome the problem of separation.

CrossMark

Within the whole population, failure to remove the CVC was significantly associated with death in model 1 (OR = 4.65, 95% confidence interval 2.28-9.48, P < 0.001). However, when care withdrawal decision and post-mortem diagnosis of candidemia were accounted for (models 2 and 3), this association disappeared (P = 0.11). The loss of significance from model 1 to the other models was observed in both ICU (P < 0.001 versus P = 0.09) and non-ICU patients (P = 0.03 versus P = 0.4), respectively. The same finding was observed when CVC infection was entered as a co-variable within the models (supplemental Table 3). These data show that failure to remove the CVC can be a consequence, rather than a cause, of death in candidemic patients. Yet, the ability to detect an association of catheter retention with death in models 2 and 3 (accounting for care withdrawal decision and post-mortem diagnosis of candidemia) compared to model 1 was



^{*}Correspondence: Oscar.Marchetti@chuv.ch; Pierre-Yves.Bochud@chuv.ch

Infectious Diseases Service, Department of Medicine, Lausanne
University Hospital, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland
Full author information is available at the end of the article

L. Damonti and V. Erard contributed equally as first authors. P.-Y. Bochud and O. Marchetti contributed equally as senior authors.

Table 1 Multivariate analyses of factors influencing crude mortality in adult candidemic patients

All patients OR 95% CI 444)° 2.12 (1.30–3.46) 0.003 2.24 (0.93–5.39) 0.07 1.55 (0.69–3.47) 0.3 1.57 (1.17–3.32) 0.011 1.51 (0.90–2.54) 0.007 2.52 (1.28–4.94) 0.007 4.65 (2.28–9.48) (2.28–9.48) 2.30 (1.03–5.15) 0.04 0.007 2.52 (1.28–9.48) 0.001 4.65 2.38 (1.03–5.15) 0.04 0.007 0.03 0.013 0.013 0.013 0.013 0.024 0.03 0.03 0.013 0.03 0.013 0.04 0.08 0.08	Characteris-	Model 1			Model 2			Model 3		
0AR 95% CI P 444)c (130-3.46) 0.003 2.12 (130-3.46) 0.003 2.24 (0.93-5.39) 0.07 1.55 (0.69-3.47) 0.3 1.97 (1.17-3.32) 0.011 1.51 (0.90-2.54) 0.12 1.79 (1.14-3.03) 0.013 2.52 (1.28-4.94) 0.007 6.45 (3.81-10.9) <0.001	5	All patients			All patients			Patients with a post-mortem diagnosis of candidemia and care withdrawal excluded	diagnosis of wal excluded	
2.12 (1.30–3.46) 0.003 2.24 (0.93–5.39) 0.07 1.55 (0.69–3.47) 0.3 1.97 (1.17–3.32) 0.011 1.51 (0.90–2.54) 0.12 1.86 (1.14–3.03) 0.013 2.52 (1.28–4.94) 0.007 4.65 (2.28–9.48) <0.001 4.65 (2.28–9.48) 0.004 2.30 (1.03–5.15) 0.04 2.30 (1.03–5.15) 0.04		OR	12% CI	Р	OR	12% CI	Ь	OR	95% CI	Р
2.12 (130-3.46) 0.003 2.24 (0.93-5.39) 0.07 1.55 (0.69-3.47) 0.3 1.97 (1.17-3.32) 0.011 1.51 (0.90-2.54) 0.12 1.86 (1.14-3.03) 0.013 2.52 (1.28-4.94) 0.007 4.65 (2.28-9.48) <0.001 4.65 (2.28-9.48) <0.001 2.30 (1.03-5.15) 0.04 3.18 (1.35-7.49) 0.008	Ⅱ patients (N =	444) ^c								
2.24 (0.93–5.39) 0.07 1.55 (0.69–3.47) 0.3 1.97 (1.17–3.32) 0.011 1.51 (0.90–2.54) 0.12 1.86 (1.14–3.03) 0.013 2.52 (1.28–4.94) 0.007 4.65 (3.81–10.9) <0.001 4.65 (2.28–9.48) <0.001 2.30 (1.03–5.15) 0.04 2.30 (1.03–5.15) 0.04 3.18 (1.35–7.49) 0.008	Age > median	2.12	(1.30–3.46)	0.003	2.01	(1.21–3.32)	0.007	2.01	(1.21–3.32)	0.007
1.55 (0.69–3.47) 0.3 1.97 (1.17–3.32) 0.011 1.51 (0.90–2.54) 0.12 1.86 (1.14–3.03) 0.013 2.52 (1.28–4.94) 0.007 4.65 (3.81–10.9) <0.001 4.65 (2.28–9.48) <0.001 2.30 (1.03–5.15) 0.04 2.30 (1.03–5.15) 0.04 3.18 (1.35–7.49) 0.008	Liver cirrhosis	2.24	(0.93–5.39)	0.07	2.11	(0.86–5.18)	0.1	2.12	(0.87–5.19)	0.1
1.55 (0.69–3.47) 0.3 1.97 (1.17–3.32) 0.011 1.51 (0.90–2.54) 0.12 1.86 (1.14–3.03) 0.013 2.52 (1.28–4.94) 0.007 4.65 (3.81–10.9) <0.001 4.65 (2.28–9.48) <0.001 2.30 (1.03–5.15) 0.04 2.30 (1.03–5.15) 0.04 3.18 (1.35–7.49) 0.008	Cancer									
1.51 (0.90-2.54) 0.011 1.51 (0.90-2.54) 0.12 1.86 (1.14-3.03) 0.013 2.52 (1.28-4.94) 0.007 1.79 (1.02-3.15) 0.04 4.65 (2.28-9.48) <0.001 4.65 (2.28-9.48) 0.004 2.30 (1.03-5.15) 0.04 3.18 (1.35-7.49) 0.008	Hematologi- cal	1.55	(0.69–3.47)	0.3	1.79	(0.81–3.97)	0.15	1.79	(0.81–3.98)	0.15
1.51 (0.90–2.54) 0.12 1.86 (1.14–3.03) 0.013 2.52 (1.28–4.94) 0.007 1.79 (1.02–3.15) 0.04 6.45 (3.81–10.9) <0.001 4.65 (2.28–9.48) <0.001 2.30 (1.03–5.15) 0.04 3.18 (1.35–7.49) 0.008	Solid tumor	1.97	(1.17–3.32)	0.011	1.92	(1.12–3.29)	0.017	1.92	(1.12–3.30)	0.018
1.86 (1.14–3.03) 0.013 2.52 (1.28–4.94) 0.007 1.79 (1.02–3.15) 0.04 6.45 (3.81–10.9) <0.001 4.65 (2.28–9.48) <0.001 = 158) ⁴ 2.30 (1.03–5.15) 0.04 3.18 (1.35–7.49) 0.008	Days in hospital >10	1.51	(0.90–2.54)	0.12	1.55	(0.91–2.65)	0.11	1.55	(0.91–2.65)	0.11
2.52 (1.28-4.94) 0.007 1.79 (1.02-3.15) 0.04 6.45 (3.81-10.9) <0.001 4.65 (2.28-9.48) <0.001 = 158) ⁴ 2.30 (1.03-5.15) 0.04 3.18 (1.35-7.49) 0.008	Parenteral nutrition	1.86	(1.14–3.03)	0.013	1.94	(1.18–3.20)	0.009	1.94	(1.18–3.20)	6000
1.79 (1.02–3.15) 0.04 6.45 (3.81–10.9) <0.001 4.65 (2.28–9.48) <0.001 = 158) ⁴ 2.30 (1.03–5.15) 0.04 3.18 (1.35–7.49) 0.008	Immunosup- pressive drugs	2.52	(1.28–4.94)	0.007	2.44	(1.24–4.79)	0.01	2.44	(1.24–4.80)	0.01
6.45 (3.81–10.9) <0.001 4.65 (2.28–9.48) <0.001 = 158) ^d 2.30 (1.03–5.15) 0.04 3.18 (1.35–7.49) 0.008	Peritonitis, postsurgical	1.79	(1.02–3.15)	0.04	1.68	(0.94–3.03)	0.08	1.69	(0.94–3.04)	0.08
4.65 (2.28-9.48) <0.001 = 158) ^d 2.30 (1.03-5.15) 0.04 3.18 (1.35-7.49) 0.008	Severe sepsis/ septic shock	6.45	(3.81–10.9)	<0.001	5.23	(3.03–9.04)	<0.001	5.24	(3.03–9.06)	<0.001
= 158) ^d 2.30 (1.03–5.15) 0.04 3.18 (1.35–7.49) 0.008	Absence of catheter removal	4.65	(2.28–9.48)	<0.001	2.08	(0.85–5.07)	0.11	2.08	(0.85–5.10)	0.11
= 158) ^d 2.30 (1.03–5.15) 0.04 3.18 (1.35–7.49) 0.008	Factors preventing optimal manage- ment ^b									
= 158) ^d 2.30 (1.03–5.15) 0.04 3.18 (1.35–7.49) 0.008	Care with- drawal				8.06	(0.36–180)	0.19			
= 158) ^d 2.30 (1.03–5.15) 0.04 3.18 (1.35–7.49) 0.008	Post- mortem diagnosis of candi- demia				35.9	(2.03–632)	0.015			
2.30 (1.03–5.15) 0.04 3.18 (1.35–7.49) 0.008	U patients (V=	158) ^d								
3.18 (1.35–7.49) 0.008	Age > median	2.30	(1.03–5.15)	0.04	2.11	(0.95–4.72)	0.07	2.13	(0.95–4.80)	0.07
	Days in hospital > 10	3.18	(1.35–7.49)	0.008	2.85	(1.23–6.58)	0.014	2.87	(1.23–6.69)	0.015

Table 1 continued

Characteris-	Model 1			Model 2			Model 3		
- <u>S</u>	All patients			All patients			Patients with a post-mortem diagnosis of candidemia and care withdrawal excluded	diagnosis of awal excluded	
	OR	D %56	Ь	OR	12 % S6	Ь	OR	12%56	Р
Parenteral nutrition	3.53	(1.50–8.35)	0.004	3,44	(1.48–8.01)	0.004	3.47	(1.48–8.14)	0.004
Severe sepsis/ septic shock	8.63	(3.59–20.8)	<0.001	6.56	(2.72–15.8)	<0.001	6.59	(2.72–16.0)	<0.001
Absence of catheter removal	12.5	(3.01–51.8)	<0.001	4.59	(0.78–27.0)	60:0	4.70	(0.77–28.7)	60.0
Factors preventing optimal management ^b	ing optimal ma	anagement ^b							
Care with- drawal				0.17	(0.00–10.5)	0.4			
Post- mortem diagnosis of candi- demia				13.4	(0.39–460)	0.15			
Non-ICU patients ($N = 286$) [¢]	$(N = 286)^{e}$								
Age > median	1.81	(0.96–3.39)	0.07	1.77	(0.93–3.40)	80:0	1.78	(0.93–3.42)	0.08
Heart disease	1.71	(0.88–3.34)	0.12	1.60	(0.80–3.21)	0.18	1.61	(0.80–3.24)	0.18
Cancer									
Hematologi- cal	66:0	(0.34–2.85)	1.0	1.11	(0.37–3.26)	6.0	1.10	(0.37–3.26)	6.0
Solid tumor	2.55	(1.29–5.02)	0.007	2.51	(1.25–5.04)	0.01	2.50	(1.24–5.02)	0.04
Immunosup- pressive drugs	3.2	(1.27–8.01)	0.013	3.18	(1.26–8.06)	0.015	3.20	(1.26–8.09)	0.014
Enterocolitis, neutropenic	3.31	(1.00–10.9)	0.05	3.06	(0.92–10.3)	0.07	3.09	(0.92–10.3)	0.07
Peritonitis, postsurgical	1.86	(0.81–4.26)	0.14	1.77	(0.75–4.18)	0.2	1.78	(0.75–4.23)	0.2
Severe sepsis/ septic shock	4.97	(2.41–10.3)	<0.001	4.38	(2.06–9.30)	<0.001	4.41	(2.07–9.40)	<0.001
Absence of catheter removal	2.80	(1.10–7.11)	0.03	1.63	(0.54-4.93)	0.4	1.65	(0.55–4.98)	0.4
Factors preventing optimal management ^b	ing optimal ma	anagement ^b							
Care with- drawal				12.8	(0.62–264)	0.01			

Table 1 continued

Characteris- Model 1	Model 1			Model 2			Model 3	
tics"	All patients	ts		All patients			Patients with a post-mortem diagnosis of candidemia and care withdrawal excluded	f ed
	OR	12 %56	Ь	OR	12 %56	Ь	OR 95% CI	d
Post-mortem				12.3	(0.49–309)	0.13		

By definition, care withdrawal and post-mortem diagnosis of candidemia (blood cultures become positive after death) are fully predictive of death and would not fit a regular logistic regression model. We used a Firth Factors associated with the endpoint (P > 0.15) were entered in the multivariate models and kept if their P value was <0.15 (supplemental Table 1)

logistic regression model [5] to overcome the problem of separation and fit these variables, thereby illustrating the bias that they introduce if not accounted for appropriately

Model 1 N=444. Model 2 N=444. Model 3 N=403

Model 1 N=158. Model 2 N=158. Model 3 N=130

Model 1 N = 286. Model 2 N = 286. Model 3 N = 273

reduced, because these models include smaller numbers of patients with a retained CVC.

In conclusion, our study points out two clinical characteristics that may be difficult to obtain but can be major confounders in the analysis of candidemia outcomes. Failure to account for these factors may contribute to overestimate the role of catheter removal in the outcome of candidemia and explain discrepant results in the literature.

Electronic supplementary material

The online version of this article (doi:10.1007/s00134-017-4737-9) contains supplementary material, which is available to authorized users.

Authors' contributions

OM designed, implemented, and coordinated the candidemia cohort study. JG, SZ, AI, KB, UF, CO, AC, TB, and OM collected clinical data, together with the clinical investigators from the centers of the FUNGINOS network listed in Appendix 1

JS, KM, RZ, TB, RF, and JB collected *Candida* blood isolates and performed species identification and antifungal susceptibility testing, together with the clinical microbiologists from the centers of the FUNGINOS network listed in Appendix 1

JB and FL coordinated the FUNGINOS reference mycology laboratory. OM coordinated the Data Review Committee composed of KB, TB, UF, JG,

LD. VE. and PYB organized the dataset and performed statistical analyses. LD, VE, OM, and PYB wrote the manuscript with the help of SZ, NK, FL, and

All authors critically revised the manuscript and accepted the final version submitted for publication.

Author details

Infectious Diseases Service, Department of Medicine, Lausanne University Hospital, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland. ² Department of Medicine, HFR-Fribourg Cantonal Hospital, Fribourg, Switzerland. ³ Infectious Diseases Service, Department of Medical Specialties, Geneva University Hospitals, Geneva, Switzerland. ⁴ Bacteriology Laboratory, Service of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland. ⁵ Institute for Infectious Diseases, University of Bern, Bern, Switzerland. ⁶ Department of Medicine, Oberaargau Hospital, Langenthal, Switzerland. ⁷ Laboratory of Microbiological Diagnostics, Institute of Medical Microbiology, University of Zürich, Zürich, Switzerland. 8 Division of Infectious Diseases and Hospital Epidemiology, Zürich University Hospital, Zürich, Switzerland. 9 Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital, Sankt Gallen, Switzerland. 10 Department of Bacteriology, Mycology and Parasitology, Center of Laboratory Medicine, Cantonal Hospital, Sankt Gallen, Switzerland. 11 Internal Medicine and Infectious Diseases, Hirslanden Klinik, Aarau, Switzerland. 12 Laboratory Medicine, Division of Clinical Microbiology, Basel University Hospital, Basel, Switzerland. 13 Internal Medicine and Infectious Diseases, Hirslanden Klinik, St. Anna, Lucerne, Switzerland. 14 Division of Infectious Diseases and Hospital Epidemiology, Basel University Hospital, Basel, Switzerland. 15 Division of Infectious Diseases and Hospital Hygiene, Cantonal Hospital, Aarau, Switzerland. 16 Clinics for Internal Medicine, Hospital Lachen AG, Lachen, Switzerland. 17 Institute of Microbiology, Department of Laboratories, Lausanne University Hospital, Lausanne, Switzerland. 18 Department of Medicine, Ensemble Hospitalier de la Côte, Morges, Switzerland.

Compliance with ethical standards

The national study has been approved by the Ethical Committee of the Lausanne University Hospital as the coordinating center. Conflicts of interest The authors have no potential conflicts of interest to declare.

Accepted: 22 February 2017 Published online: 07 March 2017

References

- Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L et al (2016) Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62:e1–e50
- Nucci M, Anaissie E, Betts RF, Dupont BF, Wu C, Buell DN et al (2010) Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 51:295–303
- 3. Horn DL, Ostrosky-Zeichner L, Morris MI, Ullmann AJ, Wu C, Buell DN et al (2010) Factors related to survival and treatment success in invasive
- candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials. Eur J Clin Microbiol Infect Dis 29:223–229
- Janum S, Afshari A (2016) Central venous catheter (CVC) removal for patients of all ages with candidaemia. Cochrane Database Syst Rev 7:CD011195
- Heinze G, Schemper M (2002) A solution to the problem of separation in logistic regression. Stat Med 21:2409–2419